Assistive Technology in Dollars: Exoskeletons, Wearables, and the Rupiah Access-Productivity Ledger

Rupiah Stability Watch · 2026-09-29

The device signal

On 27 September 2026, New Atlas reported that Wandercraft’s Eve personal exoskeleton had received U.S. FDA clearance for commercial sale: a self-balancing robotic suit for adults with spinal-cord injuries, intended to let eligible wheelchair users stand and walk hands-free in ordinary indoor settings. The underlying FDA record is more precise. Eve was cleared through the 510(k) pathway as a Class II powered exoskeleton, decision date 3 August 2026, under device code PHL. The indications say it is for people aged 18 and older with spinal-cord injury at any level who can tolerate standing and operate the controller, under supervision of a specially trained companion; it is not for sports or stairs.

That matters for Indonesia, but not because one device changes the rupiah. It matters because the device makes visible a wider cost structure already arriving through wearables, mobility aids, home monitoring, hearing and vision support, rehabilitation devices, and health software. Capability is becoming embodied in imported hardware, batteries, sensors, motors, software, service contracts, training, and spare parts.

For Rupiah Stability Watch, the ledger is narrow: when the rupiah weakens, the distance can widen between what medicine and robotics can technically make possible and what a household can use every day.

Why this belongs in the rupiah ledger

Assistive technology is not a luxury category. WHO describes it as the products and related systems and services that help people maintain or improve functioning across mobility, hearing, vision, cognition, communication, and self-care. It includes wheelchairs, prosthetic limbs, hearing aids, white canes, glasses, and digital tools. WHO’s January 2024 fact sheet says more than 2.5 billion people globally need one or more assistive products, with need projected to reach 3.5 billion by 2050. UNICEF’s page for the WHO-UNICEF Global Report adds the harder access point: nearly one billion people are denied access, and in some low- and middle-income settings access can be as low as 3 percent of need.

Indonesia’s own evidence points in the same direction, even without exoskeleton-specific access data. UNFPA’s January 2025 page for BPS-Statistics Indonesia’s 152-page portrait of persons with disabilities says the report analyzes the 2020 Population Census Long Form and the Intercensal Population Survey, covering prevalence, disability types, demographic conditions, and mobility conditions. Earlier WHO rATA training material for Indonesia flagged the basic policy problem plainly: Indonesia had people with disabilities who required assistive technology, but no valid national data on assistive technology provision.

That means the right starting point is not “will Indonesians buy exoskeletons?” It is: can Indonesia build an affordable operating model for daily-function tools before the advanced edge becomes another dollar-priced access gradient?

This extends four earlier Rupiah Stability Watch arguments. “Wearable Health Monitoring and the Rupiah” treated sensors and subscriptions as recurring household costs, not one-off gadgets. “The Medicine Import Channel” showed how imported health inputs transmit currency weakness unevenly into care. “Personalized Medicine Arrives in Dollars” and “Precision Medicine and the Rupiah” warned that advanced platforms can become access gradients when the platform, specialist chain, and maintenance layer are imported. Assistive technology sits where those arguments meet the body: if the device fails, the subscription lapses, the battery is unavailable, or the fitting service is too far away, capability disappears from the day.

The access-productivity ledger

The first side of the ledger is cost. For a frontier device like Eve, the capex is only the visible entry. Wandercraft’s own clearance announcement describes a care pathway that includes clinical assessment, individualized fitting, structured training, reimbursement assistance, and long-term support. The FDA-linked device description adds a 50.4V, 18Ah rechargeable lithium-ion battery, 12 powered degrees of freedom, software controls, fall detection, and descent controls during power failure. New Atlas reported calibration to the user’s height, leg length, and joint flexibility, four hours of charge, slow controlled movement, training, and caregiver involvement.

That is the operating ledger:

• one-time purchase or procurement;
• clinical assessment and prescription;
• fitting, calibration, and adjustment;
• structured user and companion training;
• batteries, chargers, motors, straps, pads, sensors, and controllers;
• software updates and service diagnostics;
• warranty and repair contracts;
• travel to specialist centers;
• replacement parts and customs delays;
• reliable household or clinic power;
• caregiver time during training and supervised use.

A weaker rupiah touches several of these entries. It raises the local-currency price of imported devices and parts. It makes foreign-currency service contracts more expensive for distributors, hospitals, and insurers. It can lengthen replacement cycles when households delay repairs. It can pressure public payers if reimbursement formulas do not adjust quickly enough. It can also make regional inequality sharper: Jakarta or a large provincial referral hospital may have trained technicians and distributor relationships; a household outside the specialist corridor faces travel, waiting time, and repair friction.

The second side is productivity. Assistive technology can preserve work hours, education access, and caregiver capacity. WHO’s examples are concrete: appropriate wheelchairs can improve access to education and employment while reducing secondary complications; hearing aids for young children can support language development and later participation; timely products for older people can support independence. For a household, that is not an abstract wellbeing gain. It can be fewer missed workdays, less unpaid caregiver time, fewer complications, and more participation in school or paid work.

This is the quiet economic point. Assistive technology will not defend the rupiah in the foreign-exchange market. But it can affect the household productivity base that makes a society more resilient under currency stress. The currency channel is import cost. The wellbeing channel is functioning. The policy problem is to reduce the first without losing the second.

Indonesia’s import exposure is already visible

Indonesia is not starting from a neutral supply base. The Ministry of Health’s 2023 note on cooperation with IFC says that at the start of the pandemic, 90 percent of drug raw materials were still imported and 88 percent of medical-device transactions in e-catalogs were imported products. A 2022 Ministry of Health note set a target for 60 percent of domestic medical-device production to use local components, explicitly because finished devices and raw materials were still dominated by imports.

Those figures are not about exoskeletons specifically, but they are highly relevant. Advanced assistive technology belongs to the same medical-device ecosystem: product registration, distributors, imported components, service capacity, and public procurement. If high-tech medical devices remain import-heavy, then rupiah depreciation does not only raise purchase prices. It also reaches the repair bench, the battery, the sensor, the clinic training package, and the replacement strap.

JKN/BPJS creates a partial cushion, but not a complete one. Indonesia’s benefit structure does cover some assistive devices and rehabilitation-related services, and the Ministry of Health’s 2023 tariff regulation is the current tariff reference for JKN services. The Commonwealth Fund’s 2026 Indonesia health system profile describes limited assistive-device coverage, including capped support for hearing aids and medical assistive devices such as wheelchairs and canes over multi-year periods. That is important because it confirms a public-payer channel. It also shows the likely gap: capped basic-device support does not automatically cover the full operating model for advanced embodied technology.

The least-harm reading is not that Indonesia should subsidize every frontier device immediately. It is that the country should know which assistive technologies protect the most functioning per rupiah, which imported components create the highest failure risk, and which services must be localized so a device does not become unusable after the first repair cycle.

What the evidence does not support

The evidence does not support a claim that exoskeleton adoption will strengthen the rupiah. The foreign-exchange market is moved by trade balances, capital flows, rates, credibility, commodity prices, fiscal expectations, and confidence. Assistive devices belong to the wellbeing and productivity ledger, not the exchange-rate defense toolkit.

It also does not support claiming that Eve is available in Indonesia. The verified signal is U.S. FDA clearance and U.S. commercial launch plans. I did not find reliable Indonesia-specific exoskeleton availability, reimbursement, or user-cost data in this pass. For Indonesia, Eve is best treated as a frontier cost-structure example: a concrete picture of where assistive technology is going, not evidence of current domestic access.

The evidence does not support treating technology alone as inclusion. A device without fitting, training, repair, replacement parts, safe home environments, accessible transport, and electricity is not functioning. It is inventory.

Finally, the evidence does not support reducing disability policy to productivity. Work hours and caregiver capacity matter, but the first claim is human: mobility, communication, hearing, vision, and self-care are part of dignified life. The productivity ledger is a way for economic policy to see what disability communities already know.

The least-harm operating model

Indonesia’s best response is not gadget enthusiasm. It is an access-productivity ledger with five practical columns.

First, classify assistive technologies by function preserved per rupiah. Basic devices with large reach — wheelchairs, hearing aids, prosthetics, vision supports, communication tools, pressure-injury prevention, home modifications — should remain the foundation. Frontier robotics can teach the cost structure, but should not pull attention away from underprovided basics.

Second, separate procurement from lifetime support. A hospital or payer that can buy a device but cannot maintain it has not bought capability. For imported assistive devices, tendering should price batteries, software support, calibration, training, spare parts, and service response times. If those entries are in dollars, the fiscal risk should be visible before procurement.

Third, localize the repair layer before the prestige layer. The Ministry of Health’s domestic-component target points in the right direction, but for assistive technology the most protective localization may be unglamorous: straps, pads, cushions, chargers, seating adjustments, wheelchair parts, battery diagnostics, technician training, and regional service hubs. Local repair capacity reduces downtime when the rupiah is weak and imported parts are slow.

Fourth, make JKN coverage legible to households. A benefit that exists on paper but requires repeated travel, unclear referral steps, or unaffordable top-ups will not protect functioning. The policy test is simple: can a disabled person or caregiver know what is covered, where to go, how often replacement is allowed, and what happens when the device breaks?

Fifth, treat caregivers as part of the economic ledger. Eve’s FDA indication requires a specially trained companion. Many less advanced devices also shift tasks onto family members: charging, lifting, cleaning, transporting, calibrating, and arranging repairs. If a device saves user effort but silently adds caregiver labor, the productivity gain is smaller than it looks. Training and respite matter.

What I would watch next

The most useful Indonesia indicators are not the headline price of an exoskeleton. They are more ordinary:

• the share of medical-device procurement that remains import-dependent;
• exchange-rate pass-through into assistive-device tenders and private prices;
• waiting times for wheelchairs, hearing aids, prosthetics, and rehabilitation visits;
• out-of-pocket top-ups for covered assistive devices;
• repair turnaround times outside Jakarta and major provincial centers;
• whether domestic medical-device policy includes assistive-product components, not only hospital equipment;
• whether JKN tariffs and local programs reflect lifetime support rather than purchase alone.

The rupiah question is ultimately a household question. A currency can weaken in the market and then arrive as a broken wheelchair part, a delayed hearing-aid replacement, a battery that costs too much, a clinic visit that requires a day of travel, or a caregiver who cannot keep working because the support system failed.

Assistive technology belongs on the rupiah stability ledger for that reason. It is not a currency defense. It is a test of whether Indonesia can turn imported possibility into maintained daily capability — and whether depreciation will be allowed to decide who gets to stand, hear, move, work, learn, and rest.